|
| Target | Drug type | Preclinical efficacy | Therapeutic | Clinical efficacy | |
|
| Adhesion molecules | | | | | |
| Integrins/ligands | Antisense MAdCAM-1 oligonucleotide | TNBS colitis [49, 50] | Natalizumab (humanized IgG4 mAb anti- integrin) | CD (Phase IV) [51, 52] | Prevented relapse, induced remission |
| Anti-VCAM-1 mAb | | | UC [53] | Pilot study |
| Anti-MAdCAM-1 mAb | DSS colitis [54, 55] | AJM300 (orally available anti- integrin mAB) | CD (Phase II) [56] | Reduced disease activity, good safety profile |
| Small molecule integrin antagonist | DSS colitis [22] | | | |
| Anti- and anti-MAdCAM-1 mAb | T-cell transfer colitis [57] | Vedolizumab/MLN-02 (humanized IgG4 mAb integrin) | CD [58], UC Phase II [59, 60] | Induced clinical response and remission, good safety profile |
| Anti-MAdCAM-1 mAb | SAMP1/Yit mice [61] | | | |
| Anti- mAb | Cotton top tamarin model [62] | | | |
|
| ICAM-1/LFA-1 | Anti-ICAM-1 mAb Antisense ICAM-1 oligonucleotide | DSS colitis [63, 64] | Alicaforsen (ISIS2303) (antisense ICAM-1 oligonucleotide) | UC (Phase II) [65, 66] | Reduced disease activity, good safety profile |
| Anti-ICAM-1 mAb | SAMP1/Yit mice [67] | | | |
|
| Chemokines | | | | | |
| CCR9/CCL25 | Anti-CCR9/CCL25 mAb Traficet-EN (CCX282-B) | SAMP1/Yit mice [68] TNF (DeltaARE) mice [69] | Traficet-EN/CCX282-B (small molecule CCR9 antagonist) | CD (Phase III) [70] | Induced clinical remission, good safety profile |
| CXCR3/CXCL10 | Anti-CXCL10 mAb | IL-10 KO [71, 72] DSS colitis [73] | MDX-1100 (humanized anti-CXCL10 mAb) | UC (Phase II) | NCT00295282 NCT00656890 |
|
